Kalvista Pharmaceuticals
Yahoo Finance • 11 months ago
16 Most Promising Long-Term Stocks According to Analysts
In this piece, we will take a look at the 16 most promising long-term stocks according to analysts. If you want to skip our overview of long term investing, then you can take a look at 5 Most Promising Long-Term Stocks According to Analyst... Full story
Yahoo Finance • last year
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
– Sebetralstat Phase 3 KONFIDENT Clinical Trial Achieves Target Enrollment; Data Readout Expected in Q4 – – Company Funded Into 2025 With NDA Planned for H1 2024 – CAMBRIDGE, Mass. & SALISBURY, England, July 07, 2023--(BUSINESS WIRE)--Ka... Full story
Yahoo Finance • 2 years ago
KalVista Pharmaceuticals Provides Progress Updates on Sebetralstat Development
- Phase 3 KONFIDENT clinical trial passes 50% enrollment milestone - - Topline data still expected in H2 2023 - CAMBRIDGE, Mass. & SALISBURY, England, February 14, 2023--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a c... Full story
Yahoo Finance • 2 years ago
Down More Than 60%: Analysts Say Buy These 3 Beaten-Down Stocks Before They Rebound
After the annus horribilis of 2022, with the final quarter now in play, investors will be hoping a late-year rally will materialize. According to Carson Group's chief market strategist Ryan Detrick, that’s not such a far-fetched idea. "Wh... Full story
Yahoo Finance • 2 years ago
KalVista Pharmaceuticals to Present at 1st Annual H.C. Wainwright Hereditary Angioedema Conference
CAMBRIDGE, Mass. & SALISBURY, England, July 19, 2022--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molec... Full story
Yahoo Finance • 2 years ago
KalVista Pharmaceuticals Presents Promising Preclinical Data for Oral Factor XIIa Inhibitor Program
– First preclinical data presented for structurally diverse oral Factor XIIa inhibitors - – Additional Sebetralstat data also presented - CAMBRIDGE, Mass. & SALISBURY, England, June 08, 2022--(BUSINESS WIRE)--KalVista Pharmaceuticals, In... Full story
Yahoo Finance • 2 years ago
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. & SALISBURY, England, June 03, 2022--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducem... Full story
Yahoo Finance • 3 years ago
KalVista Pharmaceuticals Announces Non-Proprietary Name Selection for KVD900
– "Sebetralstat" Approved by WHO and USAN – CAMBRIDGE, Mass. & SALISBURY, England, May 17, 2022--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development... Full story
